Pre-hospital Care With Intra-Nasal Ketamine for Transport (PRECINKT): A Pilot Study

• Status: Completed
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesize that intra-nasal ketamine, for analgesia of patients with moderate to severe pain in an alpine setting, will provide a clinically significant reduction in pain and provide an effective and feasible alternative to intravenous opioids.

The investigators wish to know:

1. Is our study protocol feasible to study INK in a mountain, prehospital care environment?

2. What estimate can be made of recruitment rates?

3. Does studying the use of INK interfere with or delay care at Whistler/Blackcomb?

4. Is intra-nasal ketamine an effective and safe method for controlling pain in our study population and setting?

5. Does intranasal ketamine provide a clinically significant reduction in pain or do patients require additional IV narcotics for extraction?

6. Are there any significant changes in vital signs after administration of intra-nasal ketamine

7. Does the use of intra-nasal ketamine reduce time of patient extraction and transport in the alpine pre-hospital setting?

8. Are there any long term sequelae of INK at one week?

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Calgary
• Collaborator: University of British Columbia
• Treatments: Ketamine

Criteria

Inclusion Criteria:

• traumatic extremity injury

• age greater than 18 years old

• moderate or severe pain (VNRS 5 or greater)

Exclusion Criteria:

• need for an intravenous catheter as judged by treating physician

• pregnancy

• unable to speak English

• shoulder dislocations,

• previous hypersensitivity, intolerance, or allergy to ketamine,

• structural or functional nasal occlusion,

• inability to understand the VNRS,

• Glasgow Coma Scale <15,

• inability to give informed consent

• history of schizophrenia